Crew Capital Management Ltd. reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 6.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,341 shares of the company’s stock after selling 405 shares during the period. Johnson & Johnson accounts for about 1.6% of Crew Capital Management Ltd.’s investment portfolio, making the stock its 16th largest holding. Crew Capital Management Ltd.’s holdings in Johnson & Johnson were worth $1,120,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of JNJ. Retirement Financial Solutions LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at $40,000. Bennett Selby Investments LP boosted its stake in Johnson & Johnson by 0.5% in the 4th quarter. Bennett Selby Investments LP now owns 17,045 shares of the company’s stock worth $3,011,000 after purchasing an additional 85 shares in the last quarter. Obsidian Personal Planning Solutions LLC increased its stake in Johnson & Johnson by 21.1% during the 4th quarter. Obsidian Personal Planning Solutions LLC now owns 2,872 shares of the company’s stock valued at $507,000 after purchasing an additional 501 shares in the last quarter. Congress Asset Management Co. MA raised its holdings in Johnson & Johnson by 3.4% in the fourth quarter. Congress Asset Management Co. MA now owns 100,568 shares of the company’s stock worth $17,765,000 after buying an additional 3,335 shares during the last quarter. Finally, Advocate Group LLC grew its holdings in shares of Johnson & Johnson by 0.5% during the fourth quarter. Advocate Group LLC now owns 78,443 shares of the company’s stock valued at $13,857,000 after buying an additional 413 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.
Analyst Ratings Changes
Several equities analysts recently issued reports on JNJ shares. Citigroup upped their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Piper Sandler dropped their price objective on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. StockNews.com started coverage on Johnson & Johnson in a research report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Guggenheim started coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $174.73.
Insider Buying and Selling
Johnson & Johnson Price Performance
Shares of Johnson & Johnson stock opened at $153.30 on Tuesday. The stock has a market cap of $399.24 billion, a P/E ratio of 22.74, a P/E/G ratio of 2.63 and a beta of 0.54. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The stock’s fifty day moving average is $159.35 and its 200 day moving average is $167.49. Johnson & Johnson has a one year low of $150.11 and a one year high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. The firm had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business’s quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the previous year, the firm earned $2.13 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.5 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is 67.06%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 3 High Yields On Breakout Watch With Analyst Tailwinds
- Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
- 3 Financials The Insiders Are Buying
- Can Carnival Cruise Lines Set Sail For New Highs?
- If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
